Pomerantz LLP Launches Class Action Against Jasper Therapeutics Due to Securities Violations

Pomerantz Law Firm Files Class Action Against Jasper Therapeutics

On September 23, 2025, the Pomerantz Law Firm announced the filing of a class action lawsuit against Jasper Therapeutics, Inc. and certain officers of the company. The lawsuit was registered in the United States District Court for the Northern District of California, case number 25-cv-08010. This legal action addresses grievances from investors who purchased or secured Jasper securities between November 30, 2023, and July 3, 2025, a period referred to as the "Class Period."

The lawsuit aims to recover damages attributed to alleged violations of U.S. securities regulations by the defendants, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. According to the complaint, there are claims that Jasper misled investors about its business practices, operations, and procedures regarding compliance, thus affecting the market’s perception of the company's securities.

Investment Community Addressed

For individuals who invested in Jasper during the Class Period, there is a crucial deadline approaching. Investors must request a lead plaintiff designation by November 18, 2025, if they wish to participate actively in the ongoing litigation. Interested parties can find a copy of the complaint on Pomerantz's official website or contact Danielle Peyton at the firm for further inquiries regarding the case.

Jasper Therapeutics Overview

Jasper Therapeutics is a clinical-stage biotechnology company engaged in developing medications aimed at treating diseases driven by mast cell activity, including Chronic Spontaneous Urticaria (CSU) and allergic asthma. Its leading candidate, briquilimab, is designed to inhibit the stem cell factor (SCF) signal that triggers mast cells, potentially providing significant therapeutic benefits for patients suffering from these conditions. The company raised $50 million in a financing round in 2024, intending to shore up its financial resources to continue its research and development.

In 2023, Jasper initiated its Phase 1b/2a clinical studies known as the BEACON Study and the ETESIAN Study, exploring briquilimab’s effectiveness in managing CSU and allergic asthma. However, on July 7, 2025, the company faced a setback when it announced potential confounding issues with one of the drug product lots used in clinical trials, leading to drastic stock value impacts. This incident brought to light concerns regarding the company’s operational controls and transparency.

Legal Allegations Detailed

The complaint outlines several critical allegations against Jasper and its executives. The defendants purportedly made false or misleading assertions about the control mechanisms over their third-party manufacturing processes necessary to comply with current Good Manufacturing Practices (cGMP). It was further claimed that such lapses not only increased risks related to the clinical trials' outcomes but also posed significant threats to the perception of the company's financial integrity.

Additionally, these failures allegedly led to exaggerated claims about the viability and potential market success of briquilimab and other therapeutic products the company was developing. Notably, after the July 2025 operational announcements, Jasper's stock dropped significantly—by over 55%, revealing the immediate financial repercussions of these alleged misrepresentations.

Market Reactions and Future Prospects

Following Jasper's concerning announcements regarding the drug lot issues and the scaling back of its clinical programs, analysts adjusted their forecasts. A report from BMO Capital Markets notably downgraded Jasper's stock, citing uncertainties surrounding the company’s operational future due to the drug lot complications and financial constraints. These insights reflect broader market apprehensions regarding Jasper's ability to navigate its development pathway effectively amidst legal troubles.

Conclusion

As the lawsuit unfolds, investors and market observers remain keenly interested in how Pomerantz LLP will address the concerns raised about Jasper Therapeutics. The unfolding circumstances highlight the delicate balance companies must maintain between advancing innovative therapies and upholding rigorous ethical and operational standards. For updates on this developing story and for interested investors, further details are available through Pomerantz's communication channels.

For inquiries or participation in the class action, Pomerantz LLP can be contacted via Danielle Peyton at 646-581-9980 or through their official website.